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  23 
Abstract 24 
In model organisms, classical genetic screening via random mutagenesis provides 25 
key insights into the molecular bases of genetic interactions, helping defining 26 
synthetic-lethality, synthetic-viability and drug-resistance mechanisms. The limited 27 
genetic tractability of diploid mammalian cells, however, precludes this approach. 28 
Here, we demonstrate the feasibility of classical genetic screening in mammalian 29 
systems by using haploid cells, chemical mutagenesis and next-generation 30 
sequencing, providing a new tool to explore mammalian genetic interactions. 31 
  32 
Classical genetic screens with chemical mutagens assign functionality to genes in 33 
model organisms1,2. Since most mutagenic agents yield single-nucleotide variants 34 
(SNVs), mutation clustering provides information on the functionality of protein 35 
domains, and defines key amino acid residues within them3. RNA interference 36 
(RNAi) allows forward-genetic screening in human cell cultures3, and insertional 37 
mutagenesis in near-haploid human cancer cells4 and whole-genome CRISPR/Cas9 38 
small-guide RNA (sgRNA) libraries have also been used for this purpose5,6. Although 39 
powerful, such loss-of-function (LOF) approaches miss phenotypes caused by 40 
separation-of-function or gain-of-function SNV mutations, are less informative on 41 
defining functional protein regions, and are not well suited to studying functions of 42 
essential genes7. Here, we describe the generation of chemically mutagenized 43 
mammalian haploid cell libraries, and establish their utility to identify recessive 44 
suppressor mutations by using resistance to 6-thioguanine (6-TG) as a proof-of-45 
principle. 46 
 47 
Comprehensive libraries of homozygous SNV-containing mutant clones are not 48 
feasible to obtain in cells with diploid genomes. To circumvent this, we used H129-3 49 
haploid mouse embryonic stem cells (mESCs)8 that we had mock-treated or treated 50 
with varying doses of the DNA-alkylating agent ethylmethanesulfonate (EMS), a 51 
chemical inducer of SNVs9 (Fig. 1a; Supplementary Results, Supplementary Fig. 52 
1a). For comparison, the same procedure was performed on diploid H129-3 mESCs 53 
(Supplementary Fig. 1b). Haploid and diploid mutant libraries were then screened 54 
for suppressors of cellular sensitivity to 6-TG (Fig. 1b). Ensuing analyses revealed 55 
EMS-dose dependent induction of 6-TG resistance, with more clones arising in 56 
haploid than in diploid cells (Fig. 1c), thus highlighting the advantage of identifying 57 
suppressor mutations in a haploid genetic background. 58 
 59 
Next, we isolated 196 6-TG resistant clones from EMS-generated haploid cell 60 
libraries. To assess the feasibility of identifying causative suppressor mutations, we 61 
subjected DNA samples from seven resistant clones, and from control mESCs not 62 
treated with EMS, to whole-exome DNA sequencing. Ensuing analyses, comparing 63 
sequences from EMS-resistant clones with control mESCs and the 129S5 mouse 64 
genome (see Methods), identified homozygous base insertions/deletions (INDELs) 65 
and SNVs. Only 11.3% of these affected coding sequences and were non-66 
synonymous (Fig. 1d). Thus, while each resistant clone had ~370 INDEL/SNV 67 
mutations (Supplementary Fig. 1c), on average only ~40 of these were in coding 68 
sequences and non-synonymous. 69 
 70 
We then identified candidate suppressor genes by analyzing this set of non-71 
synonymous mutations. We defined suppressor gene candidates as those being 72 
mutated in multiple independent clones and harboring multiple potential deleterious 73 
mutations as assigned by prediction software (see Methods and Supplementary 74 
Data Set 1). Hprt, the gene encoding the sole 6-TG target10 (Fig. 1b), was mutated 75 
in five of the seven sequenced clones (Supplementary Data Set 1). Moreover, it 76 
was the only gene mutated in multiple clones that carried likely deleterious mutations 77 
in all cases (Fig. 2a). Furthermore, these Hprt mutations affected different residues 78 
of the coding sequence (Supplementary Data Set 1). By contrast, only three non-79 
synonymous mutations in other genes mutated in more than one clone were 80 
predicted to be deleterious, and no other gene contained a likely deleterious 81 
mutation in more than one clone (Fig. 2a, Supplementary Data Set 1). This 82 
analysis established that, without using any previous knowledge regarding the nature 83 
of suppressor loci, sequencing just a few clones identified Hprt as the top 84 
suppressor-gene candidate. 85 
 86 
In addition to HPRT inactivation, mutations in genes for DNA mismatch repair (MMR) 87 
proteins confer 6-TG resistance11, as does inactivation of the DNA methyltransferase 88 
DNMT112. Notably, the two whole-exome sequenced clones that did not carry Hprt 89 
mutations contained nonsense mutations in MMR genes (Supplementary Data Set 90 
1, Supplementary Fig. 1d). To further analyze coverage of our mutant libraries, we 91 
subjected the 189 additional suppressor clones we retrieved to targeted exon 92 
sequencing of the six known suppressor genes (Fig. 1b). With the exception of 93 
Dnmt1 (see below), we identified predicted deleterious mutations in all known 94 
suppressor genes in homozygosis in two or more resistant clones (Fig. 2b top 95 
panels, Supplementary Data Set 2). Importantly, introducing wild-type versions of 96 
Hprt or Mlh1 into resistant clones containing mutations in these genes restored 6-TG 97 
sensitivity (Supplementary Figure 2), confirming them as phenotypic drivers. Thus, 98 
if the non-targeted whole-exome sequence approach that we carried out in the initial 99 
analysis of seven clones had been applied to all 196 suppressor clones, Hprt, Msh2, 100 
Msh6, Mlh1 and Pms2 would have been identified as suppressor gene candidates, 101 
confirming the feasibility of the approach to identify most or all resistance loci. 102 
 103 
Interestingly, ~20% (40) of clones presented two or more heterozygous deleterious 104 
mutations in the same suppressor gene (Supplementary Data Set 2). We note that 105 
haploid cell cultures cannot be maintained indefinitely and become diploid over 106 
time8,13. Accordingly, identified heterozygous mutations could have arisen after 107 
diploidization of the original EMS-treated haploid populations, or could have occurred 108 
in the small proportion of diploid H129-3 cells in the EMS-treated enriched haploid 109 
populations (Fig. 1a). Regardless of their origin, deleterious heterozygous mutations 110 
could only generate 6-TG resistance if each affected one allele of the gene, 111 
effectively inactivating both copies. Heterozygous mutations that we observed in 112 
Dnmt1 occurred in such close proximity that they could be analyzed from the same 113 
sequencing reads. As we observed no co-occurrence in the same reads 114 
(Supplementary Fig. 3a), we concluded that Dnmt1 mutants were compound 115 
heterozygotes, and confirmed this through Sanger sequencing (Supplementary Fig. 116 
3b). Furthermore, as these mutations all scored as potentially deleterious for DNMT1 117 
protein function (Supplementary Data Set 2), it is likely that they caused 6-TG 118 
resistance (see below). Dnmt1 would thus be included in the list of suppressor gene 119 
candidates when considering deleterious heterozygous mutations. Furthermore, this 120 
analysis increased the numbers of clones identified with mutations in other 121 
suppressor loci (Fig. 2b, lower panels). 122 
 123 
Highlighting the applicability of our methodology to identify functionally important 124 
protein regions, we retrieved variants linked to Hprt mutations causative of Lesch-125 
Nyhan syndrome14, as well as mutations in MMR genes linked to Lynch syndrome15 126 
(Fig. 2c). Partially reflecting the mutational preferences of EMS (see below), we 127 
found mRNA splicing variant mutations potentially affecting total protein levels 128 
(Supplementary Data Set 2). These were particularly prevalent in Hprt (Fig. 2b), 129 
and a detailed analysis confirmed their impacts on reducing HPRT protein levels 130 
(Supplementary Figure 4). These results highlight how production of aberrant 131 
mRNA splicing and associated reduction of protein product is an important 132 
consequence of EMS mutagenesis. 133 
 134 
We also identified mutations that had not been previously reported, the majority of 135 
which were predicted to have deleterious effects on protein function 136 
(Supplementary Fig. 5a, Supplementary Data Set 2). To verify their impacts, we 137 
introduced newly identified MLH1 (A612T) and DNMT1 (G1157E) mutations into 138 
wild-type mESCs by CRISPR/Cas9 gene editing (Supplementary Fig. 5b,c). H129-139 
3 mESCs carrying these mutations were more resistant to 6-TG than their wild-type 140 
counterparts (Supplementary Fig. 5d), supporting these mutations being causative 141 
of the suppressor phenotype. mESCs carrying targeted mutations in Dnmt1 and 142 
Mlh1 also allowed examination of their effects on cell proliferation. As observed 143 
under non-selective conditions, mutations in Mlh1, and especially in Dnmt1, impaired 144 
cell proliferation (Supplementary Fig. 5e), potentially helping to explain the low 145 
proportion of Dnmt1 mutant suppressors arising from our screen. DNMT1-deficient 146 
cells exhibit 6-TG resistance, but the mechanism for this is not completely 147 
understood12,16. Our results point to an important role of Dnmt1 methyltransferase 148 
activity in mediating 6-TG sensitivity, as suppressor mutations identified in our 149 
screen localized to that domain (Fig. 2c). Collectively, these results further validated 150 
our pipeline to identify suppressor mutations. 151 
 152 
Around 12% of resistant clones (23) did not present mutations in any of the known 153 
suppressor genes (Fig. 2b). We subjected these clones to whole-exome DNA and 154 
RNA sequencing. DNA sequencing of the unassigned clones and control samples 155 
allowed an unprecedented description of EMS mutagenic action, confirming its 156 
preference for producing SNVs and transition rather than transversion mutations 157 
(Supplementary Fig. 6). Although whole-exome sequencing retrieved causative 158 
mutations in all control 6-TG resistant samples, no other gene candidate could be 159 
identified from the remaining orphan suppressors (Supplementary Data Set 3). 160 
RNA sequencing, however, revealed reduced expression levels of Hprt, Mlh1 or 161 
Msh6 as likely causes of suppression in several such clones (Fig. 2d; 162 
Supplementary Data Set 4). Further studies will be required to define whether 163 
epigenetic alterations or mutations outside of exon regions, and hence not covered 164 
by exome-targeted DNA sequencing, could explain the nature of remaining orphan 165 
suppressor clones. 166 
 167 
Collectively, our findings establish that classical genetic screening can be effectively 168 
performed in mammalian systems by combining use of haploid cells, chemical SNV 169 
induction, and next-generation sequencing. The use of haploid cells when creating 170 
SNV mutant libraries identifies recessive suppressor point-mutations, in contrast to 171 
diploid cell screening where only dominant mutations are retrieved17. Furthermore, 172 
EMS induction of SNVs generates complex mutant libraries, increasing the 173 
probability of identifying suppressor loci compared to isolation of rare, spontaneous 174 
suppressor events18. Through screening for cellular resistance to 6-TG, we identified 175 
point mutations in all described suppressor genes. This highlights the power of our 176 
approach to comprehensively identify suppressor loci with low error rates, as no 177 
false positive suppressor candidate genes were found. Moreover, as we have 178 
established for 6-TG suppressor loci, our methodology has value in delineating key 179 
amino-acid residues required for protein function, thus helping to explain molecular 180 
mechanisms of suppression. We note that SNV-based mutagenesis will be useful to 181 
identify separation-of-function and gain-of-function mutations, including those in 182 
essential genes. Also, through studies performed in cells bearing mutations in 183 
another gene, our approach has the potential to investigate gene-gene interactions 184 
in a comprehensive manner. In addition, we envisage the applicability of this 185 
approach in human haploid cells19,20. Chemical mutagenesis of haploid cells, either 186 
alone or in combination with LOF screens, has the potential to bring functional 187 
genomics in mammalian systems to a hitherto unachieved comprehensive level. 188 
 189 
Methods 190 
Methods and associated references are available in the online version of this paper. 191 
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Figure legends 272 
 273 
Figure 1. Generation of mutagenized libraries. (a) Experimental workflow. (b) 274 
Schematic of 6-TG metabolism and genotoxicity. Inactivating mutations in genes 275 
highlighted in red have been shown to confer 6-TG resistance. (c) Suppressor 276 
frequencies to 6-TG treatment of different EMS-mutagenized libraries, represented 277 
as number of suppressor clones isolated per 10,000 plated cells. (d) Locations and 278 
consequences of identified mutations. 279 
 280 
Figure 2. Identification of suppressor mutations. (a) Genes identified through 281 
whole-exome sequencing of seven 6-TG resistant clones, harboring at least two 282 
independent mutations in different clones. Mutations were assigned as deleterious or 283 
neutral according to PROVEAN and SIFT software (see Methods). (b) Top panels. 284 
Distribution of mutations identified in suppressor gene candidates; numbers of 285 
independent clones are in brackets and types of Hprt mutations are shown in more 286 
detail on the pie-chart to the right. Bottom panels. Distribution of all suppressor gene 287 
candidate mutations identified, including heterozygous deleterious mutations. (c) 288 
Distribution of point mutations on DNMT1, HPRT and MMR proteins; each square 289 
represents an independent clone. Asterisks (*) denote STOP-codon gains. Except 290 
for HPRT, all proteins are shown at a proportional scale. (d) Hprt, Mlh1 and Msh6 291 
mRNA expression levels (fragments per kilobase per million reads). Numbers next to 292 
dots are clone identifiers (see Supplementary Data Set 2). Black dots indicate wild-293 
type (WT) samples, red dots represent clonal samples whose mutations were 294 
identified via targeted exon capture sequencing (controls; see Supplementary Data 295 
Set 2), and white dots represent samples for which no causative mutations were 296 
identified. Error bars represent uncertainties on expression estimates. Lower panel. 297 
Reduced Hprt mRNA levels correspond to reduced protein production as detected by 298 
western blot. Uncut gel images are available in Supplementary Fig. 7. 299 
300 
Online Methods 301 
 302 
Cell lines and culture conditions 303 
H129-3 haploid mouse embryonic stem cells (mESCs)8 were used for the 304 
experiments described in this paper. When pure haploid content was required, cells 305 
were grown in chemically defined 2i medium plus LIF as described previously8. In all 306 
other cases, cells were grown in DMEM high glucose (Sigma) supplemented with 307 
glutamine, streptomycin, penicillin, non-essential amino acids, sodium pyruvate, β-308 
mercaptoethanol and LIF. All plates and flasks were gelatinized prior to cell seeding. 309 
All cells used in this study were mycoplasma free. 310 
 311 
Cell sorting 312 
Cell sorting for DNA content was performed after staining with 15 μg ml−1 Hoechst 313 
33342 (Invitrogen) on a MoFlo flow sorter (Beckman Coulter). The haploid 1n peak 314 
was purified. Analytic flow profiles of DNA content were recorded after fixation of the 315 
cells in ethanol, RNase digestion and staining with propidium iodide (PI) on a 316 
Fortessa analyzer (BD Biosciences). Cell cycle profiles were produced using FlowJo 317 
software (Tree Star). 318 
 319 
Ethylmethanesulfonate (EMS) treatment 320 
Mutagenesis with EMS and measurement of killing and suppression frequency was 321 
performed as described previously9, with the following modifications. After cell 322 
sorting, haploid cells were grown in 2i medium plus LIF and changed to DMEM plus 323 
LIF for the overnight EMS treatment. After EMS treatment, cells were cultured for 5 324 
passages in DMEM plus LIF and plated into 6-well plates at a density of 5 x 105 cells 325 
per well. Cells were treated with 2 μM 6-thioguanine (6-TG; Sigma) for 6 days, 326 
supplying new media with drug daily. Cells were then grown in medium without 6-TG 327 
until mESC colonies could be picked. 328 
 329 
DNA isolation and exome sequencing 330 
mESC clones were grown into 12-well plates. Genomic DNA was extracted from 331 
confluent wells using QIAamp DNA Blood Mini Kit (QIAGEN) and cleaned performing 332 
a proteinase K (QIAGEN) digestion step. Genomic DNA (approximately 1 μg) was 333 
fragmented to an average size of 150 bp and subjected to DNA library creation using 334 
established Illumina paired-end protocols. Adapter-ligated libraries were amplified 335 
and indexed via PCR. A portion of each library was used to create an equimolar pool 336 
comprising 8 indexed libraries. For whole-exome sequencing, each pool was 337 
hybridized to SureSelect RNA baits (Mouse_all_exon; Agilent Technologies). Whole-338 
exome sequencing was performed with 8 DNA samples per sequencing lane (first 7 339 
suppressors plus control) or 15 DNA samples per sequencing lane (subsequent 66 340 
suppressors analysed). For the exon-capture experiment, samples were hybridized 341 
with a specific array of RNA baits (Agilent) covering the exonic sequences of Dnmt1, 342 
Hprt, Mlh1, Mlh3, Msh2, Msh3, Msh4, Msh5, Msh6, Pms1, Pms2 and Setd2 genes. 343 
Sequence targets were captured and amplified in accordance with manufacturer’s 344 
recommendations. Enriched libraries were subjected to 75 base paired-end 345 
sequencing (HiSeq 2500; Illumina) following manufacturer’s instructions. A single 346 
sequencing library was created for each sample, and the sequencing coverage per 347 
targeted base per sample is given in Supplementary Data Set 5. All raw sequencing 348 
data is available from ENA under accession numbers ERP003577 and ERP005179. 349 
 350 
DNA sequence analysis 351 
Sequencing reads were aligned to the Mus musculus GRCm38 (mm10) assembly 352 
(Ensembl version release 68) using BWA (v0.5.10-tpx). All lanes from the same 353 
library were merged into a single BAM file with Picard tools 354 
(http://broadinstitute.github.io/picard), and PCR duplicates were marked by using 355 
‘MarkDuplicates’21. SNVs and INDELs were called using SAMtools (v1.3) mpileup 356 
followed by BCFtools (v1.3)22. The following parameters were used for Samtools 357 
mpileup: -g -t DP,AD -C50 -pm3 -F0.2 -d10000. BCFtools call parameters were: -vm 358 
-f GQ. The variants were annotated using the Ensembl Variant Effect Predictor23. 359 
Variants were filtered to remove any variants detected outside the bait regions and 360 
any heterozygous variants where appropriate. Additionally, variants were filtered 361 
using VCFtools (v0.1.12b) vcf-annotate with options -H -f +/q=25/SnpGap=7/d=5 and 362 
custom filters were written to exclude variants with a GQ score of less than 10 24. 363 
INDELs were left aligned using BCFtools norm. VCFtools vcf-isec was used to 364 
remove variants present in the control sample from all other samples as well as 365 
variants present in sequencing of a mouse strain from the 129S5 background25. 366 
INDELs called from whole exome sequencing data were further verified using the 367 
microassembly based caller Scalpel26 and discarded from the data if not identified by 368 
both callers. All remaining variants were used to generate a visualization of 369 
mutational patterns. All SNVs were assigned to one of 96 possible triplet channels 370 
using the GRCm38 assembly to identify flanking bases. 371 
 372 
Antibodies 373 
Rabbit anti-HPRT (Abcam ab10479, 1: 10 000 dilution), mouse anti-MSH6 (BD 374 
Biosciences 610919, 1: 2 000), mouse anti-PMS2 (BD Biosciences 556415, 1: 1 375 
000), rabbit anti-MRE11 (Abcam ab33125, 1: 10 000) and mouse anti-MLH1 (BD 376 
Biosciences 554073, 1: 1 000) were used for western blot analysis. 377 
 378 
Complementation assays 379 
Human MLH1 was amplified from pEGFP-MLH127 and cloned into pPB-CMV-HA-pA-380 
IN28 using EcoRI and MluI sites to generate pPB-Tet-MLH1. Cells from the 381 
SC_6TG5758127 Mlh1 mutant clone (see Supplementary Data Set 2) were 382 
transfected with a combination of pCMV-HyPBase29, pPB-CAG-rtTAM2-IP (a 383 
derivative of pPBCAG-rtTAIRESNeo28 where the neomycin resistance cassette was 384 
replaced by a puromycin resistance one, gift from J. Hackett) and pPB-CMV-HA-pA-385 
IN or pPB-Tet-MLH1, in a 1:1:10 ratio using TransIT-LT1 transfection reagent (Mirus) 386 
and following manufacturer’s instructions. 48 h after transfection, selection was 387 
applied with 3 μg/ml puromycin for 6 days. Resistant cell populations were plated 388 
into 6-well plates (125 000 cells per well) and MLH1 expression was induced by the 389 
addition of 1 μg/ml doxycycline. 24 h after doxycycline induction, cells were left 390 
untreated or treated with 2 μg/ml 6-TG for 6 days. Surviving cells were stained using 391 
crystal violet. 392 
Cells from SC_6TG5758069 and SC_6TG5758117 Hprt mutant clones (see 393 
Supplementary Data Set 2) were transfected with pEGFP-C1 (Clontech) or pCMV6-394 
AC-Hprt-GFP (OriGene MG202453) using TransIT-LT1 transfection reagent (Mirus) 395 
and following manufacturer’s instructions. 48 h after transfection, selection was 396 
applied with 175 μg/ml G418 for several days, until GFP-positive colonies were 397 
picked. Cells were left untreated or treated with 2 μg/ml 6-TG for 6 days. Surviving 398 
cells were stained using crystal violet. Microscopy images were obtained from an 399 
Olympus IX71 microscope using CellF imaging software (Olympus). 400 
 401 
Prediction of mutation consequences on protein function 402 
Amino acid mutations were analysed using PROVEAN30 and SIFT31 software. 403 
Scores below -2.5 for PROVEAN and 0.05 for SIFT indicate likely deleterious effects. 404 
 405 
Sanger sequencing 406 
PCR amplifications from genomic DNA were performed using the following 407 
oligonucleotides: Dnmt1-1157F 5'- CGAGATGCCTGGTAGACACA -3', Dnmt1 408 
1157R 5'- GAGTAGGCCTGAGGAGAGCA -3', Dnmt1 1477F 5'- 409 
GCTACAAAACCCCAGGAAGC -3', Dnmt1 1477R 5'- 410 
CAGGATCAGATTGGCGTGAC -3'. PCR products from SC_6TG5758159 and 411 
SC_6TG5758161 Dnmt1 mutant suppressors (see Supplementary Data Set 2) were 412 
cloned using Zero Blunt TOPO PCR cloning kit (Thermo Fisher Scientific) and 413 
following manufacturer’s instructions. 414 
 415 
Gene editing 416 
Sequences for DNA templates for small guide RNAs were generated using CRISPR 417 
Design (http://crispr.mit.edu) and cloned into pAiO-Cas9 D10A32. Sequences of the 418 
guides were the following: Dnmt1-1 5'- TCGGAAGGATTCCACCAAGC -3', Dnmt1-2 419 
5'-ACATCCAGGGTCCGGAGCTT -3', Mlh1-1 5'- AGGACGACGGCCCGAAGGAA -420 
3'; Mlh1-2 5'- GCCACTTTCAGGACTGTCTA -3'. H129-3 cells were transfected with 421 
Dnmt1 or Mlh1 targeting plasmids and single-stranded DNA oligonucleotides (200 nt, 422 
IDT Technologies) containing the desired mutations using TransIT-LT1 transfection 423 
reagent (Mirus) and following manufacturer’s instructions. 48 h after transfection 424 
GFP-positive cells were sorted on a MoFlo flow sorter (Beckman Coulter) and 425 
seeded into gelatinized plates. Colonies forming after 5-6 days were picked into 96-426 
well plates, DNA was isolated using QuickExtract DNA extraction solution (Epicentre 427 
Biotechnologies) and PCR amplifications of the edited regions were performed. 428 
Sequences of the oligonucleotides used were as follows: Dnmt1-F 5'-429 
CGAGATGCCTGGTAGACACA -3', Dnmt1-R 5'- GAGTAGGCCTGAGGAGAGCA -430 
3', Mlh1-F 5'- TGTCCCAACCTAGGGACTTG -3', Mlh1-R 5'- 431 
TGCTGGCCTTAGACAGTCCT -3'. PCR products (358 bp for Dnmt1, 287 bp for 432 
Mlh1) were digested with EcoRI restriction enzyme and run on a 3% agarose 1xTAE 433 
gel for 1.5 h at 150 V. Positive clones (those producing two DNA fragments after 434 
EcoRI digestion of approx. 180 bp (Dnmt1) or 200 and 80 bp (Mlh1)) were confirmed 435 
by Sanger sequencing of the PCR products, and tested for resistance to 6-TG as 436 
described for the screen. 437 
 438 
Population doublings 439 
Each cell line was seeded in duplicate into 2 rows of a 24-well plate at a density of 440 
25 000 cells/well. Cells were collected daily and cell counts were measured using a 441 
Countess II Automated Cell Counter (ThermoFisher Scientific) using Trypan Blue 442 
staining to discard dead cells. 443 
 444 
RNA isolation and sequencing 445 
mESC clones were grown in 24-well plates. Total RNA was extracted from confluent 446 
wells using RNeasy Mini Kit (QIAGEN). Libraries for RNA-seq were prepared from 447 
500 ng total RNA using the QuantSeq 3' mRNA-Seq kit (Lexogen) according to 448 
manufacturer's instructions. An exception to the instruction was the application of 13 449 
instead of the recommended 12 PCR cycles for library amplification. Libraries were 450 
pooled in equal concentrations. Prior to sequencing, a T-fill reaction was performed 451 
on a cBot as described previously33, providing the T-fill solution in a primer tube strip. 452 
Finally, sequencing was carried out using an Illumina Hiseq-2500 using 50 bp single 453 
read v3 chemistry. Raw sequencing data is available from ENA under accession 454 
number ERP014134. 455 
 456 
RNA sequence analysis 457 
Reads were trimmed of adapter sequences using Cutadapt (v.1.2.1). High-quality 458 
reads were extracted using TriageTools34 (v0.2.2, long reads –length 35, high-quality 459 
bases –quality 9, and complex sequences –lzw 0.33). Alignments onto the mm10 460 
genome were carried out using GSNAP35 (v2014-02-28) with Gencode gene splice 461 
junctions. Expression levels were obtained using Exp3p (github.com/tkonopka/Exp3p 462 
v0.1) and then processed with custom R scripts (Supplementary Data Set 6). 463 
 464 
Statistical analyses 465 
All groups analysed showed comparable variances. 466 
 467 
Accession codes 468 
DNA sequencing data is available from ENA under accession numbers ERP003577 469 
and ERP005179. RNA sequencing data is available from ENA under accession 470 
number ERP014134. 471 
 472 
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